Actively Recruiting
Safety and Efficacy Evaluation of Sodium Hyaluronate 32mg/ml in Improving Facial Skin Dryness and Dullness
Led by IBSA Farmaceutici Italia Srl · Updated on 2025-04-06
500
Participants Needed
6
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to evaluate the safety and efficacy of sodium hyaluronate 32 mg/ml in improving facial skin dryness and dullness. Subjects are randomized to the treatment group or to the control group. Only subjects in the treatment group are treated by intradermal injection.
CONDITIONS
Official Title
Safety and Efficacy Evaluation of Sodium Hyaluronate 32mg/ml in Improving Facial Skin Dryness and Dullness
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 65 years old at time of consent
- Skin Fitzpatrick type II-IV
- Seeking temporary improvement of dry facial skin and dull complexion
- Suitable for injectable treatment as assessed by investigator
- Agree not to use other medical cosmetic treatments during study
- Voluntarily sign informed consent and able to comply with study requirements
You will not qualify if you...
- Allergy to hyaluronic acid or any product component
- History of severe allergies or autoimmune disease
- History of herpes cutis or cicatricial diathesis
- Presence of unknown injection substances in facial area
- Received permanent or semi-permanent facial fillers or face lift procedures, or plan to during study
- Received temporary dermal filler treatment within 12 months, or plan to during study
- Received botulinum toxin, mesotherapy, or facial cosmetic procedures within 6 months, or plan to during study
- Received sodium hyaluronate injections (mesotherapy) in facial area within 3 months
- Active or progressive facial skin infection or skin granuloma
- Active or progressive facial skin diseases or isomorphic reactions
- Malignant or unknown nature skin tumors on face
- Work outdoors for long periods or require sun exposure after surgery
- Excessive expectations of treatment effects
- Coagulation dysfunction or systemic diseases
- Undergoing chemotherapy or radiotherapy
- Mental illness or emotional instability
- Received thrombolytic, anticoagulant, or antiplatelet drugs within 2 weeks
- Pregnant, planning pregnancy, or breastfeeding
- Participated in other clinical trials within 1 month or currently participating
- Investigator deems unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Peking Union Medical College Hospital (PUMCH)
Beijing, China
Actively Recruiting
2
Peking University First Hospital
Beijing, China
Actively Recruiting
3
The First Principle Hospital of Changde City
Changde, China
Actively Recruiting
4
West China Hospital of Stomatology Sichuan Hospital
Chengdu, China
Actively Recruiting
5
Tongji Hospital of Tongji University
Shanghai, China
Not Yet Recruiting
6
The Second Affiliated Hospital Of Xi'an Jiaotong University
Xi'an, China
Not Yet Recruiting
Research Team
Y
Yan Wu, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here